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Calcitonin secreting neuroendocrine neoplasms of the lung: A systematic review 
and narrative synthesis.  
Abstract
Calcitonin-secreting neuroendocrine neoplasms of the lung are rare, with few cases 
reported in the literature. Differentiating between medullary thyroid carcinoma and an 
ectopic source of calcitonin secretion can represent a complex diagnostic conundrum for 
managing physicians, with cases of unnecessary thyroidectomy reported in the literature. 
This manuscript reports a case of ectopic hypercalcitonaemia from a metastatic 
neuroendocrine neoplasm of the lung with concurrent thyroid pathology and summarises the 
results of a systematic review of the literature.
Medical Literature Analysis and Retrieval System Online, Excerpta Medica, Cochrane Central 
Register of Controlled Trials, ClinicalTrials.gov and SCOPUS databases were systematically 
and critically appraised for all peer reviewed manuscripts that suitably fulfilled the inclusion 
criteria established a priori. The protocol for this systematic review was developed 
according to the Preferred Reporting Items for Systematic review and Meta-Analysis 
Protocols, and followed methods outlined in The Cochrane Handbook for Systematic Reviews 
of Interventions. This systematic review is registered with PROSPERO.
It is vital to consider diagnoses other than medullary thyroid carcinoma when presented 
with a patient with raised calcitonin, as it is not pathognomonic of medullary thyroid 
carcinoma. Lung neuroendocrine neoplasms can appear similar to medullary thyroid 
carcinoma histologically, they can secrete calcitonin and metastasize to the thyroid. 
Patients with medullary thyroid carcinoma may show stimulated calcitonin values over two 
or more times above the basal values, whereas calcitonin-secreting neuroendocrine 
neoplasms may or may not show response to stimulation tests. The present review 
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summarises existing evidence from cases of ectopic hypercalcitonaemia to lung 
neuroendocrine neoplasms. 
1. Introduction
Neuroendocrine neoplasms (NENs) are a group of tumours that can often synthesise and 
secrete biologically active substances. This can lead to an array of clinical presentations, 
also referred to as paraneoplastic syndromes (PNS) (1). 
PNS can occur as either the neoplasms acquire the ability to secrete a variety of biologically 
active substances, or by cross-reactivity between neoplastic and normal tissue (1,2,3,4). 
The secretions from neoplasms can be eutopic, meaning from an expected site of origin 
which would usually secrete such a substance, or ectopic, referring to cells that would not 
normally be associated with secretion of that substance.  The ectopic secretion of biological 
substances such as peptides, amines or cytokines are more commonly seen by neoplasms 
that are formed in the gut (2,4,5). Endocrine PNS is the term used when PNS is from ectopic 
secretion of a hormone, and can lead to diagnostic uncertainty, as it can manifest with 
symptoms identical to a neoplasm in the expected site of origin. (4,6,7).
Calcitonin (CTN) is secreted from parafollicular cells located in the thyroid gland, but also 
can be present in the lung, bladder, small intestine, liver, thymus and parathyroid glands. 
Parafollicular cells are part of the neuroendocrine system and originate from primordial C 
cells (8,9). The gene Calc-1 creates procalcitonin, which is cleaved by a convertase enzyme 
to create CTN (5). In in vitro experimental models, CTN has a temporary effect on impairing 
osteoclast function by reducing its motility, inhibiting carbonic anhydrase II and preventing 
the development of mature osteoclasts. This, along with its effects on tubular epithelium 
within the kidney, reduces serum calcium and phosphate levels (8). However, the 
significance and biological role of CTN remains elusive.
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High serum CTN concentrations may be suggestive of MTC but are not pathognomonic (9). 
MTC is a NEN originating from the thyroid and associated with eutopic secretion of CTN. 
However, CTN can also be raised due to chronic renal failure, pernicious anaemia, hepatic 
cirrhosis, various medications, extra-thyroid neoplasms, false positive CTN assay laboratory 
results, lower respiratory tract infections, smoking, chronic inflammatory conditions of the 
lung, and any condition increasing gastrin or calcium such as hyperparathyroidism or 
Zollinger-Ellison Syndrome (7,8,10,11). These conditions tend to cause a moderate rise in 
CTN compared to MTC. Extra-thyroidal NENs, however, lead to a diagnostic dilemma as they 
can be associated with similar concentrations of CTN to MTC. Extra-thyroidal sources 
associated with abnormal CTN concentration have been observed in NENs within the 
pancreas, parathyroid glands, larynx, oesophagus, thymus, lung, small intestine, liver, 
bladder and adrenals, all of which can resemble MTC histologically (3,5,10,12). 
Around 1% of normal pulmonary tissue is made up of neuroendocrine cells, which can be 
solitary cells throughout the lung or form in clusters called neuroepithelial bodies (13,14,15). 
They remain in adult lungs, and continue to secrete bioactive substances such as calcitonin, 
calcitonin gene-related peptide, serotonin, chromogranin A, and gastrin-related peptide 
(15,16,17). Physiological stimuli, such as hypoxia, can lead to such agents being secreted 
(16), which may be why Machens et al. report fluctuations of hypercalcitonaemia in patients 
with chronic lung disease (10).  There is speculation that neuroendocrine cells are the origin 
of lung NENs, but as we do not yet have evidence of the events of early cell change into 
neoplasm, this cannot be claimed definitively (16). However, around 25% of lung carcinomas 
(mainly small and large cell lung carcinomas) can develop neuroendocrine features and may 
be associated with endocrine PNS (7,14). The development of an endocrine PNS may be 
what initially leads to the diagnosis of a carcinoma, or its recurrence in cases of patients 
with known malignancy (4,18).
Page 4 of 37Accepted Manuscript published as EC-21-0071. Accepted for publication: 24-Mar-2021
Copyright © 2019 the authors Downloaded from Bioscientifica.com at 03/26/2021 10:37:02AM
via free access
4
Extra-thyroidal CTN-secreting NENs can be indistinguishable from MTC in terms of 
immunohistochemical and biochemical profiles (4,6). Due to the above similarities, biopsies 
with immunochistochemical characteristics of MTC, along with serum hypercalcitonaemia, 
could lead to an incorrect diagnosis of MTC. There have been cases of inappropriate 
thyroidectomy performed in patients with hypercalcitonaemia of extra-thyroidal origin due 
to concern of MTC (6,8). We now report the diagnostic work-up of a patient found to have 
a lung lesion and a biopsied gluteal mass with histological appearances of MTC, in the 
context of morphological thyroid gland abnormalities and concurrent hypercalcitonaemia, 
and review the relevant literature. 
2. Methodology
This protocol was developed according to the Preferred Reporting Items for Systematic 
review and Meta-Analysis Protocols (PRISMA-P), and followed methods outlined in 
The Cochrane Handbook for Systematic Reviews of Interventions15. This systematic review 
has been registered with PROSPERO (International Prospective Register of Systematic 
Reviews) with registration number CRD42021228917. 
2.1 Search Strategy
Two reviewers (DL and GKD) conducted systematic searches of the following databases: 
Medical Literature Analysis and Retrieval System Online (MEDLINE), Excerpta Medica 
(EMBASE), Cochrane Central Register of Controlled Trials (CENTRAL), ClinicalTrials.gov, 
SCOPUS databases. Our key MeSH (Medical Subject Heading) search terms were; 
“paraneoplastic” OR “ectopic” OR “neuroendocrine” AND “calciton…” AND “lung”. 
Moreover, reference lists of selected articles and other literature sources were browsed to 
ensure a comprehensive literature search was completed. None of the database searches 
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filtered results based on year of publication date, and the last search was carried out in 
January 2021.
2.2 Study Selection 
Expert opinion manuscripts, letters to the editor, commentaries, conference papers, animal 
studies, meta-analyses, and articles not in English, were excluded. Data were only included 
on adults (18 years or older), men and non-pregnant women. Articles were included if they 
examined from a lung lesion. No restrictions were made regarding the intervention type 
where a study took place, the number of participants or the duration of follow up. Covidence 
systematic review software ((Veritas Health Innovation, Melbourne, Australia; http://www. 
covidence. org) was used for manuscript screening and extraction. Publications were 
initially screened for any duplicates before being assessed independently and in parallel by 
two reviewers. Any conflicts regarding the inclusion of a study were met with discussion and 
consensus. If an agreement had not been reached, arbitration by a third reviewer was 
utilised. 
2.3 Data extraction
Data were extracted independently by two reviewers following the Cochrane Public Health 
Group Data Extraction and Assessment Template to construct our own data extraction 
template that was pilot-tested and systematically used for each article. Data extracted 
included; study description (e.g. title, primary author, publication year, type of study, 
number of participants, type of lung CTN producing neoplasm and follow-up duration). The 
primary outcome was the incidence of calcitonin-secreting lung NENs. 
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Each study was assessed for bias using the Newcastle-Ottawa scale for observational studies. 
Studies were evaluated on eight factors, categorised into three groups: selection (including 
whether the cohort is representative of the population), comparability (assessed on grounds 
of study design and the analysis performed) and outcome (i.e., the assessment of outcome, 
follow-up rate and adequacy follow-up period). 
Stars were awarded per category, with a maximum of four, two and three stars possible for 
the ‘selection’, ‘comparability’ and ‘outcome’ categories respectively. By following the 
guidelines of the Newcastle-Ottawa scale16, two reviewers assessed the studies to be of poor 
(3 stars or less), fair (4-6 stars) or good (7-9 stars) quality. 
2.5 Data Synthesis and Statistical Analysis
Heterogeneity was visually inspected, and due to the high variability and insufficient data 
results were not pooled into a meta-analysis, and a narrative synthesis was conducted 
instead.
3. Results
Our advanced search produced 327 manuscripts that were imported for screening against 
predefined criteria. There were no duplicate studies and all 327 manuscripts were screened 
against title and abstract which resulted in 29 manuscripts progressing to a full-text 
assessment. A further 6 manuscripts were excluded as they were not in English, resulting in 
23 eligible manuscripts.
The Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA-P) flow 
diagram is shown in figure 1, outlining the outcomes of the screening proce
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A 72 year-old Caucasian female presented in January 2020 with weight loss and a gluteal 
mass. She had no major co-morbidities and was not on any regular medications. She had 
noted gradual weight loss which had started since August 2019, with recurrent ear infections. 
She suffered with intermittent loose stools but no flushing, later diagnosed as terminal ileitis. 
She subsequently had a chest, abdomen and pelvis (CAP) contranst-enhanced computed 
tomography (CT) which showed bilateral pulmonary emboli, and a large 4 x 4.5cm mass 
within the right upper lobe of the lung (figure 2). Furhermore, there was evidence of a large 
retrosternal thyroid goitre and no further evidence of any intra-abdominal abnormalities. 
An enhancing lesion in the left gluteus was seen, thought to be in keeping with a soft tissue 
metastasis.
She was referred for a 18 fluoro-deoxyglucose positron emission tomography (18FDG-PET) 
which showed normal metabolic activity throughout the thyroid, including the retrosternal 
goitre. There was intense uptake (SUV max >4.5) within the 4.5cm right upper lobe lung and 
gluteal mass (figure 3). 
A biopsy of the left gluteal lesion showed fibro-fatty tissue infiltrated with malignant cells 
arranged predominantly with solid sheets. The cells had abundant eosinophilic cytoplasm 
and eccentric nuclei with frequent nuclear inclusions noted (Figure 4A). Malignant cells were 
positive for cytokeratin AE1/3, TTF1, PAX-8, synaptophysin and calcitonin, with granular 
staining for CEA (Figure 4B). Staining for chromogranin A, S100, Melan A, CD45, Napsin A, 
thyroglobulin and p40 was negative (Figure 4C). The Ki-67 proliferation index was high at 
84%. The morphology and immunophenotype was most in keeping with metastatic medullary 
thyroid carcinoma, although other metastatic neuroendocrine neoplasms could not be 
completely excluded.
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She was also referred for a neck ultrasound scan (USS) which showed a 2.6cm left confluence 
of spongiform thyroid nodules, with hypoechoic halos (U2). There was no cervical 
lymphadenopathy (figure 5). 
Following discussion in the thyroid cancer multi-disciplinary team meeting, her left thyroid 
confluence was upgraded to U4 using British Thyroid Association (BTA) guidelines (table 1) 
(12). Serum calcitonin was measured and fine needle aspiration (FNA) of the thyroid 
confluence was performed to help rule out MTC. Using BTA classification, cytology was in 
keeping with a Thy-2 sample, which maps directly to the American Bethesda Categories and 
means it was non-neoplastic (Table 2) (12). 
Calcitonin was 3900pg/ml (normal range 0-4.8), CEA 4.6ug/L (normal range 0-3.8). She was 
reviewed in the clinic, by which time she had already been on prednisolone 10mg daily to 
try and stimulate her appetite. Whilst in clinic, she reported significant polydipsia and 
polyuria, and her serum blood glucose was 21mmol/L. She was admitted for urgent inpatient 
management of steroid-induced diabetes. 
Whilst an inpatient, she was also referred for a 68Ga-DOTATATE PET/CT scan which showed 
multiple sites of progression with pleural and nodal disease (see figure 6). The finding was 
concerning of an upper right lobe lung primary with extensive right pleural and possibly 
solitary left pleural, nodal (above and below the diaphragm), and soft tissue (posterior to 
left psoas muscle ad inter left gluteal muscle) metastases.  
It was decided that, considering the results of gluteal mass histology, thyroid nodule 
cytology and imaging, the most likely diagnosis was not MTC but that of a neuroendocrine 
lung neoplasm, grade 3. This patient deteriorated rapidly and died of complications before 
any further interventions were possible. 
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CTN-secreting NENs are rare, with few reported cases in the last 20 years. Whilst small cell 
lung carcinomas (SCLC) are more commonly associated with ectopic CTN secretion, a review 
by Bondy et al. suggested that in 51% of cases it is secondary to SCLC, 20% of squamous cell, 
33% to adenocarcinoma and 33% to large cell lung carcinomas (LCLC) (19). As patients with 
ectopic CTN secretion may not display overt clinical symptoms, they might not be tested 
for serum CTN and this may be one reason for the low number of reported cases. Another 
reason for the low number of reported cases may be that raised CTN is not associated with 
characteristic symptoms distinguishing this from other PNS. 
Reported symptoms associated with raised CTN could be diarrhoea, flushing, metabolic 
alkalosis with hypokalaemia, hypocalcaemia, hypomagnesaemia, hypophosphataemia and 
hyperglycaemia (3,20). Nozières et al. showed that only one third of the patients with 
significantly raised CTN concentration above 100ng/L had symptoms such as profuse 
diarrhoea and deranged electrolytes such as hypokalaemia, hypophosphataemia, 
hypocalcaemia and metabolic alkalosis (4). There are multiple other neuroendocrine 
neoplasms causing diarrhoea such as gastrinomas, VIPomas, glucagonomas, 
somatostatinomas and the carcinoid syndrome, as well as medullary thyroid cancer and 
hypercalcitonaemia secreted from the pancreas causing Verner-Morrison syndrome (20). In 
the reported cases, when patients with CTN secreting lung NENs have clinical symptoms, 
there is usually co-secretion of other biologically-active substances, and it is these 
substances which most likely explain the symptoms rather than the raised CTN (2,3,5,7,20). 
Evidence that the frequency of hypercalcitonaemia may be higher than expected comes 
from Tsutsumi et al., who found 10 out of 45 SCLC patients were CTN immunoreactive, and 
14 out of 32 patients with bronchial carcinoid had CTN immunoreactivity on 
histopathological examination (21). Interestingly, their immunohistochemical studies 
demonstrated that bronchial carcinoids appear to imitate fetal or neonatal lung in terms of 
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calcitonin/calcitonin-gene related peptide expression. However, it was not known whether 
these patients had raised serum CTN concentrations. A significant proportion of lung 
neoplasms from that study were tested histologically and appeared to have the ability to 
express CTN, albeit patients were more often clinically asymptomatic (21). 
A summary of the study characteristics that were included in our systematic review are 
included in Table 3. It is important to note that the most isignificant  studies were performed 
before 1995: manuscripts published after 1995 are mostly case reports or small case series. 
A possible explanation for this is the method CTN was tested in the past. The initial approach 
was using radioimmunoassay, which lacked sensitivity and specificity, and so this led to a 
two-sided immunoradiometric assay developed in the late 1980s (8). In the early 2000s there 
was movement to fluorescent and chemiluminescent tests, which were more accurate. 
Enzyme-linked immunoassay (ELISA) technique was used, but an issue with ELISA was 
heterophilic antibody interference, associated with false positives or higher than actual 
values (8). One of the latest developments is the electrochemiluminescence immunoassay 
(ECLIA), which allows for a prompt and accurate diagnosis (8). This may be a reason why 
when large cohorts of patients with various NENs are randomly screened for CTN 
concentrations, such as with Daskalakis et al. (2), the percentage of them with 
hypercalcitonaemia is considerably less than several decades ago.
Coombes et al., Ellison et al. and Hillyard et al. published some of the earlier studies 
demonstrating that lung carcinomas can lead to ectopic secretion of CTN (22-24). Coombes 
et al. showed that, in 8 out of 11 patients with SCLC in their study, there was ectopic CTN 
secretion (22). 
Silva et al. showed that 52% of their 61 patients had hypercalcitonaemia (25). They also 
demonstrated that if the patient had a clinical response to treatment, this would be 
mirrored by a decrease in CTN concentration. Hansen et al. measured CTN concentrations 
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in 75 patients with SCLC and found elevated CTN in 48 patients (26). Multiple patients in 
this study also had co-secretion of either ACTH or vasopressin (ADH). Hansen et al. found 
that there was no correlation with CTN and stage of disease, meaning higher CTN 
concentrations were not associated with more extensive disease (26).
Hansen et al. questioned whether previous studies reporting on the incidence of 
hypercalcitonaemia in their cohorts was due to infiltrative bone disease (27). None of the 
74 patients from their cohort had hypercalcaemia, albeit two thirds had hypercalcitonaemia. 
They found that when comparing different stages of the disease, there was no significant 
difference to CTN concentration, and that bone metastases did not lead to CTN elevations. 
CTN concentrations were in the range expected for MTC. In another study, Hansen et al. 
found that CTN concentration was not predicting response to treatment comparing 
responders to non-responders (28). 
Hansen et al. performed a detailed follow-up of patients with hypercalcitonaemia (29). 
Their study had three arms and all patients in their study had SCLC. In the first arm, 6 
patients with raised CTN concentrations had blood tests taken prior to their chemotherapy 
which consisted of cyclophosphamide and vincristine. Blood samples were then repeated at 
regular intervals over a week. 4 out of 6 patients had raised baseline CTN concentrations, 
and in those 4 patients there was a significant decrease in CTN levels at one week following 
treatment. The second arm had baseline blood tests prior to chemotherapy, 3-6 months 
later, and then again if there was evidence of disease relapse: 11 patients in this arm had 
baseline CTN concentrations exceeding 79pg/ml and tumour partial or complete response 
to treatment. In this group, 9 of 11 patients who responded to treatment also had a 
significant reduction in CTN. Eight of these 9 patients then had tumour relapse, with a 
subsequent rise in CTN concentration. However, this rise was only moderate, albeit disease 
symptoms were clinically significant, indicating that CTN was not a useful prognostic marker. 
The results suggested that only in a small proportion of patients would CTN be of prognostic 
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value, but no consistent patient characteristics were identified. Only 3 patients with 
hypercalcitonaemia in remission were followed up to 18 months after treatment initiation. 
Their CTN concentrations had only been moderately increased at baseline and remained 
stable after 18 months follow up. 
Gropp et al. used a higher pathological CTN cut off (>125pg/ml), and abnormal results were 
observed in 26 out of 54 patients with SCLC. There was no positive or negative correlation 
to disease stage (30). CTN concentrations would decrease if there was agood response to 
treatment and rise in poor responders but findings were only numerically significant. In a 
study by Coombes et al., whilst higher baseline serum CTN values were associated with a 
poorer response to treatment, it was recommended that measuring serum CTN to predict 
response to treatment should be kept to a minimum (31). 
Tabolli et al. reported a high incidence of hypercalcitonaemia, with 53.6% of their 41 
bronchogenic carcinomas showing a raised CTN, but unlike Gropp et al. they did not provide 
information regarding their histopathological characteristics (32). As concentrations were 
regularly increased in patients with malignant neoplasms, CTN was felt to be a useful marker.
Roberts et al. presented a case of a patient with hypercalcitonaemia and amylase co-
secretion. The patient also had raised adrenocorticotrophic hormone (ACTH), raised growth 
hormone, and raised luteinising hormone (33). Sano et al. discuss a patient with lung 
carcinoid co-secreting somatostatin and CTN (34). A particularly rare case of ectopic co-
secretion of 6 hormones including CTN from one tumour was reported by Monsieur et al. 
(17). Melanin production in MTC and lung carcinoid tumours leading to diagnostic 
uncertainty has been reported by Eagle et al.  (35). Initially, the diagnosis was thought to 
be primary amelanotic choroidal melanoma with choroidal metastases. However, detailed 
investigations confirmed a primary lung carcinoid (35). 
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In a study of patients with untreated SCLC, Samuels et al. demonstrated no relationship 
between CTN concentration and disease stage or survival rate (36). On review of previous 
studies, they estimated that 25–66% of patients with SCLC have elevated CTN concentrations 
at the time of diagnosis; 71% of their 69 patients had elevated CTN, but the only significant 
result found was hypercalcitonaemia in liver metastases, with hypercalcitonaemia having a 
sensitivity of 100% but a specificity of only 41% and a positive predictive value of 40%. As 
with Hansen et al., there was no significant difference to CTN concentrations in case of 
metastatic bone disease (27). 
Kelley et al. designed a study with 3 arms, including non-smokers without SCLC, smokers 
without SCLC, and smokers with SCLC (10). All but one of the 49 patients smoked in the 
SCLC group. They were able to demonstrate that in the two groups without SCLC, smoking 
appeared to moderately increase CTN. Kelley et al. also demonstrated in a murine animal 
model that air pollution or smoking increased the number of pulmonary neuroendocrine 
cells that were positive for CTN on immunohistochemical staining, and that smoking 
appeared to cause hyperplasia of the pulmonary neuroendocrine cells. In their human study, 
CTN concentrations were not correlated with severity of smoking. Interestingly, 6 patients 
with SLCL had negative staining for CTN on immunohistochemistry, but elevated serum CTN. 
Like in other cases of PNS with peripherally-raised hormone but negative staining, one 
theory for this may be that SCLC cells may have acquired the ability to secrete CTN but 
have not completely altered their machinery to express this histologically. It was concluded 
that the use of CTN was not a reliable marker for monitoring treatment response (10). 
Interestingly, on immunohistochemical studies of 2 of the reported studies reported in Table 
3, there was negative CTN tissue staining but raised serum levels, similar to the findings of 
Kelley et al. (10,11,20). Pratz et al. (20) hypothesised that large cell lung carcinoma (LCLC) 
cases they described co-secreted VIP and CTN. One theory was that LCLC tumours from their 
study were biologically behaving like a VIPoma, in which cells rapidly secrete CTN reaching 
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high serum concentrations, and so may not be seen expressed within the tumour cells. An 
alternative theory was that the neoplasm secretes an as yet unknown substance which 
stimulates CTN secretion from C cells. Whilst there can be other causes of 
hypercalcitonaemia (7,8,10), these would not induce CTN elevation as such reported by 
Pratz et al. (20).
Coners et al. reported the first case of SCLC co-secreting ACTH and CTN (3). Cvijovic et al. 
presented a patient with multinodular goitre, neck lymphadenopathy, raised CTN and raised 
carcinoembryonic antigen (CEA), who was referred to them initially with the diagnosis of 
MTC (7). Surgical excision of the lymph node showed this to be a metastasis from a 
neuroendocrine neoplasm, with bronchoscopy confirming the diagnosis (7). 
Similarly, Vahidi et al. report a case of suspected MTC but with an incidental lung lesion 
seen on a chest x-ray and biopsy suggesting either MTC or other NEN. Both cases by Cvijovic 
et al. and Vahidi et al. are similar to our case as thyroid FNA was required to help rule out 
MTC (6,7).
Daskalaskis et al. performed a large retrospective study of more than 700 patients with 
NENs to describe the incidence of endocrine paraneoplastic syndromes (2). Only 4 patients 
were found to have hypercalcitonaemia, but the study included patients with multiple NEN 
sites not just originating from the lung. One of these patients was documented as having a 
lung carcinoid. All 4 patients had stage IV disease, and all 4 were described having 
concurrently other endocrine PNS with hypercalcitonaemia. This study highlights the rarity 
of lung NENs secreting CTN (2). 
Machens et al. and Hansen et al., focused on the use of CTN stimulation tests to look at 
whether CTN secreting NENs can be distinguished from MTC based on response to calcium 
or pentagastrin tests. Whilst Machens et al. suggested that MTC tends to be associated with 
a doubling CTN concentration following stimulation, Hansen et al. warned that there can 
Page 15 of 37 Accepted Manuscript published as EC-21-0071. Accepted for publication: 24-Mar-2021
Copyright © 2019 the authors Downloaded from Bioscientifica.com at 03/26/2021 10:37:02AM
via free access
15
still be a significant CTN rise in lung NENs, and that high CTN response to stimulation is not 
pathognomonic for MTC (9, 37). 54 of the 79 patients had hypercalcitonaemia prior to 
pentagastrin test, with 25% of them having CTN concentrations expected of MTC. 
In the largest recent study of CTN secreting NENs, Nozières et al. reviewed the data of 17 
patients with lung NENs secreting CTN (5). Nine of these patients had high CTN 
concentrations over 100ng/l at diagnosis. Whilst Nozières et al. did not demonstrate an 
association between CTN concentrations and prognosis, patients whose CTN concentration 
was >100ng/l had higher grade neoplasms. They suggest testing for CTN in patients with 
foregut NENs and diarrhoea (5).
6. Conclusions
This work highlights the importance of considering differentials to MTC when presented with 
thyroid pathology and hypercalcitonaemia, and that although raised serum calcitonin 
suggests MTC, it is not pathognomonic. Our review of the literature highlights conflicting 
results when interpreting CTN role in predicting biological behaviour, response to treatment 
or overall survival rates in cases of patients with ectopic hypercalcitonaemia to lung NENs. 
The interpretation of elevated serum calcitonin is still a matter of debate given the many 
confounding factors, variety of assays with limited efficacy and different cut-offs. We 
propose a thorough clinical evaluation of all patients presenting with elevated CTN 
concentration followed by multidisciplinary discussion when planning investigations and 
therapy to avoid misdiagnosis of ectopic CTN sources of secretion.
Acknowledgements:  The authors of this manuscript sought to locate family members and 
therefore ask permission to publish this fully anonymised report after this patient died but 
Page 16 of 37Accepted Manuscript published as EC-21-0071. Accepted for publication: 24-Mar-2021
Copyright © 2019 the authors Downloaded from Bioscientifica.com at 03/26/2021 10:37:02AM
via free access
16
were unsuccessful in locating them. The authors of this manuscript report no conflicting 
interests. 
References: 
1. Georgios K Dimitriadis, Anna Angelousi, Martin O Weickert, Harpal S Randeva, 
Gregory Kaltsas, Ashley Grossman. Paraneoplastic endocrine syndromes. Endocr 
Relat Cancer. 2017 Jun;24(6):R173-R190.doi: 10.1530/ERC-17-0036. Epub 2017 Mar 
24.
2. Daskalakis K, Chatzelis E, Tsoli M, Papadopoulou-Marketou N, Dimitriadis GK, 
Tsolakis AV, Kaltsas G. Endocrine paraneoplastic syndromes in patients with 
neuroendocrine neoplasms. Endocrine. 2019 May;64(2):384-392. doi: 
10.1007/s12020-018-1773-3. Epub 2018 Oct 2. PMID: 30280284; PMCID: PMC6531606.
3.  Coners K, Woods SE, Webb M. Dual paraneoplastic syndromes in a patient with small 
cell lung cancer: a case report. J Med Case Rep. 2011 Jul 19;5:318. doi: 
10.1186/1752-1947-5-318. PMID: 21771301; PMCID: PMC3158120.
4. Nozières C, Chardon L, Goichot B, Borson-Chazot F, Hervieu V, Chikh K, Lombard-
Bohas C, Walter T. Neuroendocrine tumors producing calcitonin: characteristics, 
prognosis and potential interest of calcitonin monitoring during follow-up. Eur J 
Endocrinol. 2016 Mar;174(3):335-41. doi: 10.1530/EJE-15-0917. Epub 2015 Dec 15. 
PMID: 26671974.  
Page 17 of 37 Accepted Manuscript published as EC-21-0071. Accepted for publication: 24-Mar-2021
Copyright © 2019 the authors Downloaded from Bioscientifica.com at 03/26/2021 10:37:02AM
via free access
17
5. Vahidi S, Stewart J, Amin K, Racila E, Li F. Metastatic medullary thyroid carcinoma 
or calcitonin-secreting carcinoid tumor of lung? A diagnostic dilemma in a patient 
with lung mass and thyroid nodule. Diagn Cytopathol. 2018 Apr;46(4):345-348. doi: 
10.1002/dc.23852. Epub 2017 Nov 10. PMID: 29124912. 
6. Cvijovic G, Micic D, Kendereski A, Zoric S, Sumarac-Dumanovic M, Tatic S, Trivic A, 
Pejkovic-Stamenkovic D, Jeremic D. Ectopic calcitonin secretion in a woman with 
large cell neuroendocrine lung carcinoma. Hormones (Athens). 2013 Oct-
Dec;12(4):584-90. doi: 10.14310/horm.2002.1447. PMID: 24457407. 
7. Giannetta E, Guarnotta V, Altieri B et al., ENDOCRINE TUMOURS: Calcitonin in 
thyroid and extra-thyroid neuroendocrine neoplasms: the two-faced
Janus. Eur J Endocrinol. 2020 Dec;183(6):R197-R215. doi: 10.1530/EJE-20-0506. 
PMID: 33112280.
8. Gambardella C, Offi C, Clarizia G, et al., Medullary thyroid carcinoma with double 
negative calcitonin and CEA: a case report and update of literature review. BMC 
Endocr Disord. 2019 Oct 16;19(1):103. doi: 10.1186/s12902-019-0435-7. PMID: 
31619220; PMCID: PMC6794852.
9. Machens A, Haedecke J, Holzhausen HJ, Thomusch O, Schneyer U, Dralle H. 
Differential diagnosis of calcitonin-secreting neuroendocrine carcinoma of the 
foregut by pentagastrin stimulation. Langenbecks Arch Surg. 2000 Oct;385(6):398-
401. doi: 10.1007/s004230000169. PMID: 11127524. 
10. Kelley MJ, Becker KL, Rushin JM, et al.,Calcitonin elevation in small cell lung cancer 
without ectopic production. Am J Respir Crit Care Med. 1994 Jan;149(1):183-90. doi: 
10.1164/ajrccm.149.1.8111580. PMID: 8111580.
11. Ghillani PP, Motté P, Troalen F, et al. Identification and measurement of calcitonin 
precursors in serum of patients with malignant diseases. Cancer Res. 
1989;49(23):6845-6851.
Page 18 of 37Accepted Manuscript published as EC-21-0071. Accepted for publication: 24-Mar-2021
Copyright © 2019 the authors Downloaded from Bioscientifica.com at 03/26/2021 10:37:02AM
via free access
18
12. Sui P, Wiesner DL, Xu J, Zhang Y, et al,. Pulmonary neuroendocrine cells amplify 
allergic asthma responses. Science. 2018 Jun 8;360(6393):eaan8546. doi: 
10.1126/science.aan8546. Epub 2018 Mar 29. PMID: 29599193; PMCID: PMC6387886.
13. Naizhen X, Linnoila RI, Kimura S. Co-expression of Achaete-Scute Homologue-1 and 
Calcitonin Gene-Related Peptide during NNK-Induced Pulmonary Neuroendocrine 
Hyperplasia and Carcinogenesis in Hamsters. J Cancer. 2016 Oct 23;7(14):2124-2131. 
doi: 10.7150/jca.16399. PMID: 27877229; PMCID: PMC5118677.
14. Weichselbaum M, Sparrow MP, Hamilton EJ, Thompson PJ, Knight DA. A confocal 
microscopic study of solitary pulmonary neuroendocrine cells in human airway 
epithelium. Respir Res. 2005 Oct 10;6(1):115. doi: 10.1186/1465-9921-6-115. PMID: 
16216130; PMCID: PMC1277851.
15. Song H, Yao E, Lin C, Gacayan R, Chen MH, Chuang PT. Functional characterization 
of pulmonary neuroendocrine cells in lung development, injury, and tumorigenesis. 
Proc Natl Acad Sci U S A. 2012 Oct 23;109(43):17531-6. doi: 
10.1073/pnas.1207238109. Epub 2012 Oct 9. PMID: 23047698; PMCID: PMC3491514.
16. Gosney JR, Sissons MC, Allibone RO. Neuroendocrine cell populations in normal 
human lungs: a quantitative study. Thorax. 1988 Nov;43(11):878-82. doi: 
10.1136/thx.43.11.878. PMID: 3065973; PMCID: PMC461542.
17. Monsieur I, Meysman M, Noppen M, de Greve J, Delhove O, Velckeniers B, Jacobvitz 
D, Vincken W. Non-small-cell lung cancer with multiple paraneoplastic syndromes. 
Eur Respir J. 1995 Jul;8(7):1231-4. doi: 10.1183/09031936.95.08071231. PMID: 
7589410.
18. Mitchell AL, Gandhi A, Scott-Coombes D, Perros P. Management of thyroid cancer: 
United Kingdom National Multidisciplinary Guidelines. J Laryngol Otol. 2016 
May;130(S2):S150-S160. doi: 10.1017/S0022215116000578. PMID: 27841128; PMCID: 
PMC4873931.
Page 19 of 37 Accepted Manuscript published as EC-21-0071. Accepted for publication: 24-Mar-2021
Copyright © 2019 the authors Downloaded from Bioscientifica.com at 03/26/2021 10:37:02AM
via free access
19
19. Bondy PK. The pattern of ectopic hormone production in lung cancer. Yale J Biol Med. 
1981 May-Jun;54(3):181-5. PMID: 6270916; PMCID: PMC2595956.
20. Pratz KW, Ma C, Aubry MC, Vrtiska TJ, Erlichman C. Large cell carcinoma with 
calcitonin and vasoactive intestinal polypeptide-associated Verner-Morrison 
syndrome. Mayo Clin Proc. 2005 Jan;80(1):116-20. doi: 10.1016/S0025-
6196(11)62968-6. PMID: 15667039. 
21. Tsutsumi Y. Immunohistochemical analysis of calcitonin and calcitonin gene-related 
peptide in human lung. Hum Pathol. 1989 Sep;20(9):896-902. doi: 10.1016/0046-
8177(89)90103-2. PMID: 2550350. 
22. Coombes RC, Hillyard C, Greenberg PB, MacIntyre I. Plasma-immunoreactive-
calcitonin in patients with non-thyroid tumours. Lancet. 1974 Jun 1;1(7866):1080-3. 
doi: 10.1016/s0140-6736(74)90557-1. PMID: 4135248.
23. Ellison M, Woodhouse D, Hillyard C, Dowsett M, Coombes RC, Gilby ED, Greenberg 
PB, Neville AM. Immunoreactive calcitonin production by human lung carcinoma cells 
in culture. Br J Cancer. 1975 Sep;32(3):373-9. doi: 10.1038/bjc.1975.237. PMID: 
1233082; PMCID: PMC2024744.
24. Hillyard CJ, Coombes RC, Greenberg PB, Galante LS, MacIntyre I. Calcitonin in breast 
and lung cancer. Clin Endocrinol (Oxf). 1976 Jan;5(1):1-8. PMID: 942890.
25. Silva OL, Broder LE, Doppman JL, Snider RH, Moore CF, Cohen MH, Becker KL. 
Calcitonin as a marker for bronchogenic cancer: a prospective study. Cancer. 1979 
Aug;44(2):680-4. doi: 10.1002/1097-0142(197908)44:2<680::aid-
cncr2820440240>3.0.co;2-j. PMID: 476577.
26. Hansen M, Hansen HH, Hirsch FR, Arends J, Christensen JD, Christensen JM, Hummer 
L, Kühl C. Hormonal polypeptides and amine metabolites in small cell carcinoma of 
the lung, with special reference to stage and subtypes. Cancer. 1980 Mar 
15;45(6):1432-7. doi: 10.1002/1097-0142(19800315)45:6<1432::aid-
cncr2820450622>3.0.co;2-z. PMID: 6244082.
Page 20 of 37Accepted Manuscript published as EC-21-0071. Accepted for publication: 24-Mar-2021
Copyright © 2019 the authors Downloaded from Bioscientifica.com at 03/26/2021 10:37:02AM
via free access
20
27. Hansen M, Rehfeld JF, Stadil F. Small cell carcinoma of the lung: relation of 
calcitonin to bone marrow metastases, parathormone and gastrin. Acta Med Scand. 
1979;206(3):215-8. doi: 10.1111/j.0954-6820.1979.tb13497.x. PMID: 227233.
28. Hansen M, Hammer M, Hummer L. Diagnostic and therapeutic implications of ectopic 
hormone production in small cell carcinoma of the lung. Thorax. 1980 Feb;35(2):101-
6. doi: 10.1136/thx.35.2.101. PMID: 6246651; PMCID: PMC471231.
29. Hansen M, Hammer M, Hummer L. ACTH, ADH, and calcitonin concentrations as                                                                                                                                    
markers of response and relapse in small-cell carcinoma of the lung. Cancer. 1980 
Nov 1;46(9):2062-7. doi: 10.1002/1097-0142(19801101)46:9<2062::aid-
cncr2820460926>3.0.co;2-x. PMID: 6253049.
30. Gropp C, Havemann K, Scheuer A. Ectopic hormones in lung cancer patients at 
diagnosis and during therapy. Cancer. 1980 Jul 15;46(2):347-54. doi: 10.1002/1097-
0142(19800715)46:2<347::aid-cncr2820460223>3.0.co;2-s. PMID: 6248192.
31. Coombes RC, Dearnaley DP, Ellison ML, Neville AM. Markers in breast and lung cancer. 
Ann Clin Biochem. 1982 Jul;19 (Pt 4):263-8. doi: 10.1177/000456328201900415. PMID: 
6127052.
32. Tabolli S, Valtorta C, Scarda A, D'Erasmo E, Minisola S, Antonelli R, Medori C, 
Mazzuoli G. Plasma calcitonin and tumors. Tumori. 1983 Jun 30;69(3):227-30. PMID: 
6868140.
33. Roberts I, Chopra S, Warshaw AL. Carcinoma of the lung with marked 
hyperamylasemia and elevated serum calcitonin. Am J Gastroenterol. 1982 
Jan;77(1):43-4. PMID: 6175207.
34. Sano T, Saito H, Yamasaki R, Hamaguchi K, Ooiwa K, Shimoda T, Hosoi E, Saito S, 
Hizawa K. Immunoreactive somatostatin and calcitonin in pulmonary neuroendocrine 
tumor. Cancer. 1986 Jan 1;57(1):64-8. doi: 10.1002/1097-
0142(19860101)57:1<64::aid-cncr2820570114>3.0.co;2-6. PMID: 2866833.
Page 21 of 37 Accepted Manuscript published as EC-21-0071. Accepted for publication: 24-Mar-2021
Copyright © 2019 the authors Downloaded from Bioscientifica.com at 03/26/2021 10:37:02AM
via free access
21
35. Eagle RC Jr, Ehya H, Shields JA, Shields CL. Choroidal metastasis as the initial 
manifestation of a pigmented neuroendocrine tumor. Arch Ophthalmol. 2000 
Jun;118(6):841-5. doi: 10.1001/archopht.118.6.841. PMID: 10865324.
36. Samuels T, Cameron R, Hirte H, Osoba D, Malkin DG, Malkin A. Imaging studies and 
the prognostic value of serum calcitonin in staging small-cell lung cancer. Tumour 
Biol. 1987;8(4):211-7. doi: 10.1159/000217524. PMID: 2834815.
37. Hansen M, Hansen HH, Tryding N. Small cell carcinoma of the lung: serum calcitonin 
and serum histaminase (diamine oxidase) at basal levels and stimulated by 
pentagastrin. Acta Med Scand. 1978;204(4):257-61. doi: 10.1111/j.0954-
6820.1978.tb08436.x. PMID: 211804.
Figure legends:
Figure 1: Flow diagram demonstrating the breakdown of the screening process.
Figure 2: CT scan with transverse plane view of the 4 x 4.5cm right upper lobe lung 
lesion.
Figure 3: 18FDG PET coronal CT displaying two avid lesions, in the right upper lobe 
and left gluteal region.
Figure 4A:  Haematoxylin & Eosin staining of the left gluteal lesion composed of 
sheets of cells with abundant eosinophilic cytoplasm and eccentric nuclei with 
stippled chromatin, some with nuclear pseudo-inclusions. 25 mitotic figures / 2mm 
slides.
Figure 4B: Positive immunoperoxidase staining, x100 magnification, A: 
Synaptrophysin, B: Calcitonin, C: PAX8, D: TTF1
Figure 4C: Negative immunoperoxidase staining, x100 magnification, A: 
thyroglobulin, B: chromogranin
Figure 5: Thyroid USS demonstrating a 2.6cm left confluence of spongiform thyroid 
nodules, with hypoechoic halos (U2). No cervical lymphadenopathy.
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Figure 6: 68Ga-DOTATATE PET/CT scan with arrows pointing to the upper lobe 
primary, pleural and nodal disease.
Table legends:
Table 1: U grading of thyroid nodules based on ultrasound imaging. 
Table 2: Thy diagnostic grading for fine needle aspiration cytology (FNAC). 
Table 3: Characteristics of CTN secreting lung NEN Studies.
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Figure 1 – flow diagram demonstrating the breakdown of the screening process 
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Figure 2 – CT scan with transverse plane view of the 4 x 4.5cm right upper lobe lung lesion. 
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Figure 3 – 18FDG PET coronal CT displaying two avid lesions, in the right upper lobe and left gluteal 
region. 
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Figure 3A:  Haematoxylin & Eosin staining of the left gluteal lesion composed of sheets of cells with abundant 
eosinophilic cytoplasm and eccentric nuclei with stippled chromatin, some with nuclear pseudo-inclusions. 25 
mitotic figures / 2mm slides. 
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Figure 3C: Negative immunoperoxidase staining, x100 magnification, A: thyroglobulin, B: chromogranin 
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Figure 5 -  Thyroid USS demonstrating a 2.6cm left confluence of spongiform thyroid nodules, with 
hypoechoic halos (U2). No cervical lymphadenopathy.  
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Figure 6 –68Ga-DOTATATE PET/CT scan with arrows pointing to the upper lobe primary, pleural and 
nodal disease.  
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U grading of thyroid nodules
U1 U2  U3          U4                    U5
normal benign indeterminate/equivocal            suspicious                malignant
Normal Halo Homogenous          Solid Hypo-echoic
thyroid Iso-echoic or mildly Hyper-echoic          Hypo-echoic or Lobulated or
tissue hyperechoic solid, halo (follicular          very hypo-echoic irregular
Cystic change ± ring lesion)              Disrupted peripheral  outline
Down sign micro-cystic Equivocal echogenic foci          calcification                  Micro-calcific.
/spongiform. Peripheral Cystic change mixed/          lobulated outline Globular 
Egg shell calcification central vascularity calcification 
Peripheral vascularity Intra-nodular                      
vascularity






No follow-up No follow-up required FNAC           FNAC FNAC
Required - routine FNAC not 
recommended unless
high clinical suspicion of
thyroid cancer
FNAC = fine needle aspiration cytology
Table 1: U grading of thyroid nodules based on ultrasound imaging (18)
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Thyroid FNAC diagnostic categories
Thy1 Thy2 Thy3              Thy4 Thy5
           Thy 3F Thy 3A
Non- diagnostic Non-          Follicular lesion Atypia present          Suspicious of Diagnostic of




Repeat FNAC No follow -       Diagnostic Repeat ultrasound           Discuss at MDT               Discuss at MDT
up if no          hemithyroidectomy* and FNAC           Diagnostic Appropriate
suspicious        Consider total If second Thy 3 A           hemithyroidectomy further 
US features      Thyroidectomy in cytology obtained, investigations
and no          lesions >4cm where discuss at MDT and for staging 
clinical          incidence of consider diagnostic                where indicated
suspicion          malignancy is higher hemithyroidectomy Total thyroid-





FNAC = fine needle aspiration cytology
Table 2: Thy diagnostic grading for fine needle aspiration cytology (FNAC) (18)
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Table 3: Characteristics of CTN secreting lung NEN Studies









Assessment of outcome NOS
Star 
Award
Coombes et al 
1974 (22)
UK All SCLC Prospective Not 
mentioned
46 >100 Not mentioned Increased CTN concentrations 
of not diagnostic of MCT
8
Ellison et al, 
1975 (23)
UK Likely poorly 
differentiated squamous 
carcinoma
Case Report 18 months 1 2580 No Cells in vitro had stable heritable 
characteristic of immunoreactive 
CT synthesis and release.
NA
Hillyard et al 
1976 (24)
UK All SCLC Prospective Not 
followed-up
31 2500, 2200, 
890, 4900
Not mentioned That lung could cause ectopic 
production of CTN
8
Hansen et al 
1978 (37)
Denmark 38% adenocarcinoma, 




79 109 Not mentioned
CTN frequently elevated in 
SCLC, and a positive 
pentagastrin test is not 
pathognomonic for MTC
8
Silva et al 
1979 (25)




be >300, range 
300 to 17500
Not mentioned CTN may be a useful marker to 
assess results of therapy in 
bronchogenic cancer. 52% had 
raised CTN
7
Hansen et al 
1979 (27)
Denmark All SCLC Prospective Not 
mentioned
74 Up to 55000 Not mentioned Bone metastases have no 
influence on CTN 
concentrations. Results 
resemble concentrations seen 
in MTC. 2/3 patients had 
raised CTN
8
Hansen et al 
1980 (26)
Denmark All SCLC Prospective Not 
followed-up
75 1300 Not mentioned CTN is not correlated with 
stage of disease
8
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Table 3: Characteristics of CTN secreting lung NEN Studies









Assessment of outcome NOS
Star 
Award
Hansen et al 
1980 (28)




CTN raised in 65% of their 
patients.   No significant 
different to stage of disease, 
response to treatment or 
survival
7
Hansen et al 
1980 (29)





Not mentioned Initial response to treatment, 
decrease with treatment when 
there is disease regression. 
Moderate increase to CTN with 
relapse, albeit disease symptoms 
clinically significant and so 
deemed not useful for relapse
9
Gropp et al 
1980 (30)
Germany All SCLC Prospective Not followed-up 110 Concentrations 
had to be 
above 125
Not mentioned CTN elevated in 26/54 SCLC, 4/41 
squamous cell, 2/19 large cell.  CTN 
concentrations dropped with 
treatment and rise if a poor 
response. Does not correlate with 
stage of disease
8




29% SCLC, 22% 
squamous cell, 
13% LCLC
Case report Died before 
treatment 
commenced
1 >1000 Not mentioned Rapidly deteriorated and died 
before treatment
N/A
Tabolli et al 
1983 (32)
Italy All SCLC Prospective Not followed-up 41 >57 
females, >97 
males
Not mentioned As concentrations were often higher 
in people with cancer, it was felt to 
be a good marker.
8
Sano et al 1986 
(34)
Japan All SCLC Case report 6 months 1 340 No CTN returned to normal after 
surgical resection. However, 
suggestive of bone metastasis 6 
months after surgery.
N/A
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Table 3: Characteristics of CTN secreting lung NEN Studies











Assessment of outcome NOS
Star 
Award
Samuels et al 
1987 (36)
Canada All SCLC Retrospective Not mentioned 127 Mean value 1300 Up to 999, but 
majority <500
No significant difference with CTN 
concentrations and stage of malignancy 
or survival
8
Kelley et al 
1994 (10)
USA All SCLC Prospective Not mentioned 86 concentrations > 79 647 CTN nit a good marker for treatment 
response. CTN raised if a smoker
7
Monsieur et al 
1995 (17)
Belgium Adenocarcinoma Case report Died before 
treatment 
commenced
1 Concentrations had to 
be > 125
65500 Rapid deterioration and died, treatment 
not commenced
N/A
Eagle et al 
2000 (3





Germany All SCLC Prospective Not followed-
up




Pentagastrin stimulation test can lead to 
significant rises in MTC in non-MTC
7
Pratz wt al 
(20)




1 340 9571 Cisplatin and etoposide saw 2-week 
transient improvement but patient then 
deteriorated and died
N/A
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Table 3: Characteristics of CTN secreting lung NEN Studies
Study Country Type of 
neoplasm









Assessment of outcome NOS
Star 
Award
Coners et al 
2011 (3)
USA SCLC Case report Died after 1st 
cycle of 
treatment
1 81.8 Diarrhoea thought 
not to be due to 
CTN
Somatostatin, cisplatin and etoposide saw 
moderate improvement to CTN concentrations, 
but patient deteriorated and died after 1st cycle 
of treatment
N/A
C vijovic et al 
2013 (6)
Serbia LCLC Case report Patient died 
after 7th cycle 
of treatment
1 260 No 6 cycles of cisplatin and etoposide saw 
moderate improvement to CTN concentrations. 
One cycle of Peptide Receptor Radionuclide 
Therapy, but patient deteriorated and died
N/A
Nozières et al 
2015 (4)
France Study does 
not specify 
type, 4 out 
of 17 were 
documented 
as carcinoid





8 out of 11 patients who were followed up had 
highest CTN concentration before death. 4 of 
these 11 patients had lung neoplasms, all which 
carcinoid. The trend towards poor survival if 
high CTN was not significant. No correlation 
with CTN and staging. 
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Sweden Carcinoid Retrospective Mean follow 
up 89.6 
months
834 Unknown but 
had to be >10 to 
be included in 
study
Potentially, but 
could be explained 
by short colonic 
transit times
All 4 patients with raised CTN had disseminated 
disease at diagnosis. All 4 were described 
together with another endocrine PNS.
8
SCLC= small cell lung carcinoma, CTN= calcitonin, LCLC=large cell lung carcinoma, MTC=medullary thyroid carcinoma, 
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